Search Results - "Conley BA"

Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2a.

Authors: Fleming GF Waggoner SE Wu S et al.

Source: JNCI: Journal of the National Cancer Institute. 01/15/97, Vol. 89 Issue 2, p172-173. 2p.

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

Authors: Kummar S Song Z Reiss KA et al.

Source: JCO precision oncology [JCO Precis Oncol] 2026 Jun; Vol. 10 (6), pp. e2500769. Date of Electronic Publication: 2026 Jun 17.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

Authors: Coleman N Wei Z Iafrate AJ et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Apr 01; Vol. 32 (7), pp. 1224-1233.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.

Authors: Akhave N Song Z Hong DS et al.

Source: JCO precision oncology [JCO Precis Oncol] 2026 Feb; Vol. 10, pp. e2500612. Date of Electronic Publication: 2026 Feb 20.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF^V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

Authors: Salama AKS Wang V Macrae ER et al.

Source: JCO precision oncology [JCO Precis Oncol] 2026 Jan; Vol. 10, pp. e2500338. Date of Electronic Publication: 2026 Jan 14.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.

Authors: McCourt CK Wei Z Kalinsky K et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4912-4919.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

Authors: Tsao AS Song Z Ho AL et al.

Source: JCO precision oncology [JCO Precis Oncol] 2025 Oct; Vol. 9, pp. e2500119. Date of Electronic Publication: 2025 Oct 09.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.

Authors: Zane LK Yee LM Chang TC et al.

Corporate Authors: Zane LK Yee LM Chang TC et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Aug 14; Vol. 31 (16), pp. 3512-3525.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

Authors: Janku F Jegede OA Puhalla SL et al.

Source: JCO precision oncology [JCO Precis Oncol] 2025 Aug; Vol. 9, pp. e2500265. Date of Electronic Publication: 2025 Aug 27.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.

Authors: Gouda MA Wei Z Rodon J et al.

Source: JCO precision oncology [JCO Precis Oncol] 2025 Feb; Vol. 9, pp. e2400451. Date of Electronic Publication: 2025 Feb 06.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.

Authors: O'Hara MH Jegede O Dickson MA et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jan 06; Vol. 31 (1), pp. 56-64.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.

Authors: Gien LT Song Z Poklepovic A et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Dec; Vol. 8, pp. e2400514. Date of Electronic Publication: 2024 Dec 12.

Publication Type: Journal Article; Clinical Trial, Phase II; Adaptive Clinical Trial; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

Authors: Zauderer MG Jegede O Jackman DM et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Dec; Vol. 8, pp. e2400327. Date of Electronic Publication: 2024 Dec 18.

Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

Authors: Mansfield AS Wei Z Mehra R et al.

Source: NPJ precision oncology [NPJ Precis Oncol] 2022 Mar 01; Vol. 6 (1), pp. 13. Date of Electronic Publication: 2022 Mar 01.

Publication Type: Journal Article

Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.

Authors: Gettinger SN Song Z Reckamp KL et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Jul; Vol. 8, pp. e2300725.

Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Authors: Connolly RM Wang V Hyman DM et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 01; Vol. 30 (7), pp. 1273-1280.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

Authors: Chen MF Song Z Yu HA et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300454.

Publication Type: Clinical Trial, Phase II; Journal Article; Adaptive Clinical Trial; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.

Authors: Gong J Mita AC Wei Z et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300406.

Publication Type: Clinical Trial, Phase II; Journal Article; Adaptive Clinical Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

Authors: Gong J Mita AC Wei Z et al.

Source: JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300407.

Publication Type: Clinical Trial, Phase II; Journal Article; Adaptive Clinical Trial

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

Authors: Conley BA Staudt L Takebe N et al.

Source: Journal of the National Cancer Institute [J Natl Cancer Inst] 2021 Jan 04; Vol. 113 (1), pp. 27-37.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE